Actuate Therapeutics, Inc. Common stock
ACTUHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeActuate Therapeutics, Inc. Common stock operates in the Biotechnology space. Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. Valued at $32.3M, ACTU is a micro-cap name in its sector. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Market Cap
$32.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-1.59
EPS (TTM)
$-0.95
EPS (Fwd)
$-0.85
ROE
—
ROA
-203.8%
Cash
$8.1M
Total Debt
$0
Free CF
-$11.8M
52W Change
-78.4%
Annual Financials
Cash vs Debt
Where ACTU stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ACTU finished 51.27% below its 150-day moving average ($3.55) and 60.50% below its 200-day moving average ($4.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACTU overbought or oversold?
At the July 15, 2026 close, ACTU's RSI(14) was 44.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Actuate Therapeutics, Inc. Common stock reports $8.1M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$11.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ACTU.